-
1 Comment
Forte Biosciences, Inc is currently in a long term downtrend where the price is trading 9.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Forte Biosciences, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 56.8% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 65.9% to $-4M since the same quarter in the previous year.
Based on the above factors, Forte Biosciences, Inc gets an overall score of 3/5.
| CurrencyCode | USD |
|---|---|
| Industry | Biotechnology |
| Sector | Healthcare |
| Exchange | NASDAQ |
| ISIN | US34962G1094 |
| Dividend Yield | 0.0% |
|---|---|
| Market Cap | 23M |
| PE Ratio | None |
| Beta | 1.39 |
| Target Price | 3.5 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for FBRX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
